Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures (S29.006)

Picchione et al. (Tue,) studied this question.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults (P8-1.011)2024 · 2 citations
2. 2Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007)2024 · 8 citations
3. 3Discovery and Evaluation of E0714 as an Antiepileptic Candidate: A Highly Subtype-Selective Kv7 Agonist within the Kv7 Family Designed Based on a Kv7.2-Specific Pocket2026 · 3 citations
4. 4BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002)2024 · 1 citations
5. 5Quantitative EEG analysis of brivaracetam in drug-resistant epilepsy: A pharmaco-EEG study2024 · 9 citations